Jacobs & Co. CA raised its stake in Sanofi SA (NYSE:SNY) by 3.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,855 shares of the company’s stock after acquiring an additional 400 shares during the period. Jacobs & Co. CA’s holdings in Sanofi were worth $549,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in SNY. Ibex Wealth Advisors acquired a new stake in shares of Sanofi in the second quarter valued at approximately $25,000. Heritage Wealth Advisors boosted its holdings in shares of Sanofi by 141.2% in the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after acquiring an additional 353 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Sanofi by 292.4% in the second quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares during the period. Prestige Wealth Management Group LLC acquired a new stake in shares of Sanofi in the second quarter valued at approximately $37,000. Finally, Evolution Wealth Advisors LLC acquired a new stake in shares of Sanofi in the second quarter valued at approximately $40,000. Institutional investors own 7.04% of the company’s stock.
Shares of NYSE SNY traded up $0.38 during mid-day trading on Friday, hitting $45.86. 1,911,995 shares of the company were exchanged, compared to its average volume of 1,307,250. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The stock has a 50 day simple moving average of $45.85 and a 200-day simple moving average of $43.37. Sanofi SA has a 1-year low of $40.00 and a 1-year high of $47.47. The firm has a market cap of $114.86 billion, a price-to-earnings ratio of 14.65, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67.
Several research firms have recently weighed in on SNY. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Thursday, August 29th. Guggenheim raised Sanofi from a “neutral” rating to a “buy” rating in a report on Monday, September 23rd. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Thursday, August 29th. Morgan Stanley raised Sanofi from an “equal” rating to a “weight” rating in a report on Friday, September 20th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, October 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $49.50.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: Understanding the different types of bonds
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.